Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 15/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GCGR | P47871 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25044591 | 0.88 | RIPK3 (0.52) | RIPK3MAPK14CSNK1DMAPK13MAPK12 | |
| SCHEMBL30232366 | 0.87 | RIPK3 (0.49) | RIPK3MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL30232556 | 0.86 | RIPK3 (0.50) | RIPK3MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL28878620 | 0.86 | MAPK14 (0.51) | RIPK3MAPK14ALOX5FAAHCSNK1D | |
| SCHEMBL23410469 | 0.84 | GRIA1 (0.52) | RIPK3MAPK14ALOX5FAAHMAPK13 | |
| SCHEMBL29974708 | 0.83 | GRIN2B (0.42) | RIPK3MAPK14FAAH | |
| SCHEMBL23410299 | 0.79 | MAPK14 (0.56) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL29974820 | 0.79 | MAPK14 (0.46) | RIPK3MAPK14MAPK11 | |
| SCHEMBL25044524 | 0.79 | KCNH2 (0.43) | RIPK3MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL23410499 | 0.78 | MAPK14 (0.53) | RIPK3MAPK14ALOX5MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052017-A1 | New compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-02-16 | — | — | US | disclosed |
| US-20230052017-A1 | New compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230052017-A1 | New compounds for treatment of diseases related to DUX4 expression | SMN1; SMN2, UTRN, DDX21 | RIPK3 3338/4885MAPK14 4274/4885ALOX5 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.